Literature DB >> 26155513

Multiple Sclerosis Like Condition in a Patient of Hepatitis C after Treatment with Interferon Alpha: A Case Report.

Pyar Ali Fazil1, Syed Mustafa Ali2, Mustafa Zaboli2, Syed Raza Shah3.   

Abstract

Hepatitis C virus affects millions of people around the world. The primary therapy comprises of interferon alpha and ribavarin. The most common side effects of this treatment include flu like symptoms and psychiatric issues. One of the rare complications of the combined therapy is the development of demyelinating lesions in the central nervous system. Our case report presents a 35-year-old man who was a known case of Hepatitis C presenting to us with altered level of consciousness and decreased vision. He had been treated as per the standard therapy for Hepatitis C infection with interferon alpha and ribavarin. During the course of this therapy, he developed significant loss of vision. This was in fact due to serious and rare complication of the treatment which was demonstrated on the MRI as demyelinating lesions in the deep periventricular white matter bilaterally. Visual Evoked Potential study was performed which concluded bilateral dysfunction of the optic pathway. The treatment of Hepatitis C with interferon alpha and ribavarin may present with a wide array of adverse effects which includes a rare complication of central nervous system demyelination as well. Research suggests that early treatment of Multiple Sclerosis (MS) is beneficial in the long run with a better prognosis and minimal changes on MRI of the patient. Therefore this complication of the treatment should be kept in mind as one of the main differential diagnosis. By finding the extent of the inflammation, and consequently doing an MRI alongside a lumbar puncture, can serve to diagnose a rare condition mimicking multiple sclerosis while treating with interferon alpha.

Entities:  

Keywords:  MRI; Optic neuritis; White and gray matter

Year:  2015        PMID: 26155513      PMCID: PMC4484105          DOI: 10.7860/JCDR/2015/12588.5962

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  9 in total

Review 1.  PSG consensus statement on management of hepatitis C virus infection--2003.

Authors:  S Hamid; M Umar; A Alam; A Siddiqui; H Qureshi; J Butt
Journal:  J Pak Med Assoc       Date:  2004-03       Impact factor: 0.781

Review 2.  Management of chronic hepatitis C.

Authors:  V Lo Re; J R Kostman
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

Review 3.  Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?

Authors:  Manuel A Friese; Lars Fugger
Journal:  Brain       Date:  2005-06-23       Impact factor: 13.501

Review 4.  Painful and involuntary multiple sclerosis.

Authors:  Francesca Bagnato; Diego Centonze; Simonetta Galgani; Maria Grazia Grasso; Shalom Haggiag; Stefano Strano
Journal:  Expert Opin Pharmacother       Date:  2011-02-17       Impact factor: 3.889

Review 5.  Hepatitis C treatment: current and future perspectives.

Authors:  Saira Munir; Sana Saleem; Muhammad Idrees; Aaliyah Tariq; Sadia Butt; Bisma Rauff; Abrar Hussain; Sadaf Badar; Mahrukh Naudhani; Zareen Fatima; Muhmmad Ali; Liaqat Ali; Madiha Akram; Mahwish Aftab; Bushra Khubaib; Zunaira Awan
Journal:  Virol J       Date:  2010-11-01       Impact factor: 4.099

6.  Multiple sclerosis-like disease secondary to alpha interferon.

Authors:  Toshihiko Matsuo; Ryu Takabatake
Journal:  Ocul Immunol Inflamm       Date:  2002-12       Impact factor: 3.070

7.  Fulminant central nervous system demyelination associated with interferon-alpha therapy and hepatitis C virus infection.

Authors:  R Höftberger; F Garzuly; H P Dienes; J Grubits; B Rohonyi; G Fischer; Z Hanzely; H Lassmann; H Budka
Journal:  Mult Scler       Date:  2007-11       Impact factor: 6.312

8.  Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection.

Authors:  Vijay Khiani; Thomas Kelly; Adeel Shibli; Donald Jensen; Smruti R Mohanty
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

9.  Acute inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alfa-2a in a patient with chronic hepatitis C virus infection: a case report.

Authors:  Mounia Lahbabi; Meryem Ghissassi; Faouzi Belahcen; Sidi Adil Ibrahimi; Nouredine Aqodad
Journal:  J Med Case Rep       Date:  2012-09-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.